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The International Agency for Research on Cancer (IARC) Monographs program reevaluated
polychlorinated dibenzo-p-dioxins and evaluated polychlorinated dibenzofurans as possible
carcinogenic hazards to humans in February 1997, using the most recent epidemiologic data on
exposed human populations, experimental carcinogenicity bioassays in laboratory animals, and
supporting evidence on relevant mechanisms of carcinogenesis. 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (TCDD) was evaluated as carcinogenic to humans (IARC group 1 classification) on the basis
of limited evidence of carcinogenicity to humans derived from follow-up of workers who had
been heavily exposed in industrial accidents and sufficient evidence of carcinogenicity in
experimental animals. The evaluation also considered the following supporting evidence: TCDD is
a multisite carcinogen in experimental animals and has been shown by several lines of evidence
to act through a mechanism involving the aryl hydrocarbon receptor; this receptor is highly
conserved in an evolutionary sense and functions the same way in humans as in experimental
animals; tissue concentrations of TCDD are similar in heavily exposed human populations in
which an increased overall cancer risk was observed and in exposed rats that developed tumors
in carcinogenicity tests. Other polychlorinated dibenzo-p-dioxins, the nonchlorinated dibenzo-p-
dioxin, and polychlorinated dibenzofurans were evaluated as not classifiable as to their
carcinogenicity to humans (group 3).- Environ Health Perspect 106(Suppl 2):755-760 (1998).
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The program ofthe International Agency
for Research on Cancer (IARC) Monographs
on the Evaluation ofCarcinogenic Risks to
Humans convened a Working Group of
experts and observers from 11 countries in
Lyon, France, 4 to 11 February 1997 to
evaluate the evidence that polychlorinated
dibenzo-p-dioxins (PCDDs) and polychlori-
nated dibenzofurans (PCDFs) might be risk
factors for human cancer (1). Although
quantitative information, including dose-
response relationships, was important in
reaching the conclusions ofthe meeting, the
question ofquantitative risk estimation was
not addressed by the Working Group. This
meeting marked the third time PCDDs
were considered within this program. In
1977 few data were available and no evalua-
tion of PCDDs could be made, either on
the basis ofanimal carcinogenicity evidence
or reports ofpeople exposed to contami-
nated herbicides (2). By 1987 the animal
carcinogenicity data had developed to the
stage where there was sufficient evidence for
the carcinogenicity of 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD or dioxin,
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the PCDD that has caused most concern),
but the epidemiologic evidence remained
inadequate (3). Accordingly, at that time
TCDD was evaluated aspossiblycarcinogenic
to humans (IARC group 2B classification),
whereas all other PCDDs were considered
notclassifiable as to their carcinogenicity to
humans(group 3).
Occurrence and Exposure
to PCDDs and PCDFs
PCDFs are formed as inadvertent by-
products in the production and use of
polychlorinated biphenyls (PCBs) and, in
combination with PCDDs, in the produc-
tion ofchlorophenols; PCDFs have been
detected as contaminants in these products
(4-6). PCDFs and PCDDs also may be
produced in thermal processes such as
incineration and metal processing and in
the bleaching ofpaper pulp with free chlo-
rine (7-9). PCDFs also are found in resid-
ual waste from the production ofvinyl
chloride and the chloralkali process for
chlorine production (10-14). The relative
amounts of PCDF and PCDD congeners
produced depend on the production or
incineration process and varywidely.
PCDDs and PCDFs are ubiquitous in
soil, sediment, and air. Descriptions of
exposure and biologic monitoring informa-
tion can be found in Polychlorinated
Dibenzo-para-Dioxins andPolychlorinated
Dibenzofurans (1). Excluding occupational
or accidental exposures, most human expo-
sure to PCDDs and PCDFs occurs as a
result ofeating meat, milk, eggs, fish, and
related products, as both PCDDs and
PCDFs are persistent in the environment
and accumulate in animal fat. Occupational
exposures to both PCDDs and PCDFs at
higher levels have occurred since the 1940s
as a result of the production and use of
chlorophenols and chlorophenoxy herbi-
cides; PCDF exposure also results from
metal production and recycling. Even
higher exposures to PCDDs have occurred
sporadically in relation to accidents in these
industries. High exposures to PCDFs have
occurred as a result ofaccidents involving
electrical equipment containing PCBs (15)
and from the consumption ofcontaminated
rice oils. The latter have caused specific ill-
nesses to which the locally descriptive names
for oil disease have been given: Yusho in
Japan (16) andYu-cheng in Taiwan (17).
In human tissues, current mean back-
ground levels ofTCDD are in the range of
2 to 3 ng/kg fat; the sum ofthe penta- and
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hexachlorinated PCDF congeners com-
monlyfound in human tissues is generallyin
the range of10 to 100 ng/kg fat. Tissue con-
centrations following accidental exposures
have led to increases above these background
levels ofup to four orders ofmagnitude for
TCDD and one or more orders ofmagni-
tude for PCDFs. Because ofthe long half-
lives ofmany ofthese substances in humans
(e.g., approximately 7 years for TCDD), a
single acute exposure from the environment
results in the exposure ofpotential target tis-
sues over many years; this property also
allows accurate extrapolation ofconcentra-
tions in tissues back to the known dates of
accidental exposure, thereby permitting esti-
mation ofindividual levels ofacute exposure
with unusuallyhigh precision.
Evidence forthe
Carcinogenicity of PCDDs
Human CarcinogenicityData
The most informative studies for causal
inference are those in which it is clear that
the highest exposures to the chemical in
question have occurred because, ifthey are
causal, these will produce the highest cancer
risks. For this reason, attention focused on'
the most exposed subcohorts within cohorts
with adequate latency, although other
cohort studies and numerous case-control
studies also played a role in the evaluation.
Following these criteria, the most important
studies for the evaluation ofTCDD are four
cohort studies ofherbicide producers [one
each in the United States (18) and the
Netherlands (19), two in Germany
(20,21)]. These studies involve the highest
exposures to TCDD among all epidemio-
logic studies. The cohort ofresidents in a
contaminated area from Seveso, Italy, iswell
known, but the exposures at Seveso were
lower and the follow-up shorter than those
in the industrial settings (22). Most ofthe
four industrial cohorts include analyses of
subcohorts considered to have the highest
exposure and/or longest latency. Additional
cohort and case-control studies ofherbi-
cide applicators (23), military personnel in
Vietnam, as well as Operation Ranch
Hand personnel (24), who have consider-
ably lower exposures to TCDD, were not
considered critical for the evaluation.
An increased risk for all cancers
combined (approxmately 1.4-fold) was seen
in the cohort studies. This magnitude of
increase occurred in subcohorts considered
to have theheaviest TCDD exposure within
the cohorts. Furthermore, statistically
significant positive dose-response trends for
all cancers combined were present in the
largest and most heavily exposed German
cohort (21). A positive trend (p=0.05) was
also seen in the smaller German cohort
where an accident occurred with release of
large amounts ofTCDD; the positive trend
in this cohort was limited to smokers (20).
Cumulative dose in both these trend analy-
ses was estimated by combining data from
blood and adipose tissue TCDD levels and
knowledge ofjob categories, work processes,
and dates ofexposure. This information was
used with elimination half-time data in
kinetic models for extrapolation back to the
time ofaccidental exposure. Increased risks
for all cancers were also seen in the longer
duration, longer latency subcohort of a
study in the United States (18,25). These
positive trends with increased exposure tend
to reinforce the overall positive association
between all cancers combined and exposure,
making it less likely that the increase is
explained by confounding, either by smok-
ing or by other carcinogenic exposures in
industrial settings.
An increased risk oflung cancer is also
present in the most informative cohort
studies, again especially in the more highly
exposed subcohorts. The relative risk for
lung cancer in the combined highly exposed
subcohorts was estimated to be 1.4 (statisti-
cally significant). It is possible that lung
cancer relative risks ofthis order could result
from confounding by smoking, but only if
there is a pronounced difference in smoking
habits between the exposed population and
the referent populations, a difference that
seems unlikely. It therefore seems unlikely
that confounding by smoking can explain
all the excess lung cancer risk, although it
could explain part ofit. It is also possible
that other occupational carcinogens, many
ofwhich would affect the lung, are causing
some confounding. Several other malignant
neoplasms have been reported sporadically
to be at increased prevalence in some popu-
lations exposed to TCDD, but none of
these were consistendy increased within the
individual cohorts. For example, soft-tissue
sarcomas were present in the Seveso popula-
tion, but only in the zone that overall had
the lowest exposure (25); no such increase
was present in the German (20,21) or
Dutch (19) cohort studies.
Overall, the strongest evidence for the
carcinogenicity ofTCDD is for all cancers
combined rather than for any specific site.
There are few examples ofagents that cause
an increase in cancers at many sites; exam-
ples are smoking and ionizing radiation in
atomic bomb survivors (for both agents,
however, there are clearly elevated risks for
certain specific cancer sites). This lack of
precedent for a multisite carcinogenwithout
particular sites predominating means that
the epidemiologic findings must be treated
with caution. On the basis ofthis informa-
tion, it was considered that there is limited
evidence in humans for the carcinogenicity
ofTCDD.
In contrast, there was inadequate evi-
dence in humans for the carcinogenicity of
all other PCDDs.
AnimalCarcinogenicty Data
In a number ofexperiments with rats and
mice in which TCDD was administered,
increases in the incidence ofliver tumors
were consistently found in both males and
females. In addition, several other neo-
plasms were increased in rats, mice, and
Syrian hamsters, induding thyroid follicular
cell adenomas, lymphomas, and alveolar/
bronchiolar adenomas and carcinomas; but
these effects were dependent on the species,
sex, and route ofadministration ofTCDD.
In addition, tumors developed at a number
ofunusual sites such as the tongue, hard
palate, and nasal turbinates in rats (26-31).
Although they are extremely low, the doses
resulting in increased tumor incidence in
rodents are very close to doses that are toxic
in the same species. These data led to the
condusion that there is sufficient evidence in
experimental animals for the carcinogenicity
ofTCDD. It is notable that the tissue con-
centrations ofTCDD in one ofthe studies
with rats given doses thatproduced asignifi-
cant increase in tumor incidence were in the
same range as those experienced in some
highlyexposedhuman populations.
Evaluation of much smaller databases
(32,33) led to the conclusion that there
is limitedevidence in experimental animals
for the carcinogenicity of a mixture of
1,2,3,6,7,8- and 1,2,3,7,8,9-hexaCDD and
that there was inadequate evidence for the
carcinogenicity in experimental animals of
2,7-diCDD, 1,2,3,7,8-pentaCDD, and
1,2,3,4,6,7,8-heptaCDD. The nonchlori-
nated dibenzo-p-dioxin has been thor-
oughly tested in rodents, with negative
results (33).
Evidence forthe
Carcinogenicity of PCDFs
Human CarcinogenicityData
Two incidents, one in Japan (Yusho)
(35,36) and one in Taiwan (Yu-cheng)
(37), each involving about 2000 cases,
involved individuals' exposure to sufficient
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doses of PCBs and PCDFs to produce
symptoms. Fatal liver disease is now 2 to 3
times more frequent than national rates in
both cohorts. In Japan there is a 3-fold
excess of liver cancer mortality in men,
which was already detectable and even
higher at 15 years than after 22 years of
follow-up. In Taiwan, after 12 years offol-
low-up, there is no excess ofliver cancer
mortality. Based on these data it was con-
cluded that there is inadequate evidence in
humans for the carcinogenicity ofPCDFs.
AnimalCarcinogenictyData
There are no long-term carcinogenicity
studies on PCDFs, but some tumor pro-
motion studies were evaluated in which
rats and mice were exposed to some ofthe
congeners following short-duration expo-
sure to known carcinogens (38-41). It was
concluded that there is inadequate evidence
in experimental animals for the carcino-
genicity of2,3,7,8-tetrachlorodibenzofuran
but there is limited evidence in experimen-
tal animals for the carcinogenicity of
2,3,4,7,8-pentaCDF and 1,2,3,4,7,8-
hexaCDF.
Other Effects
The large number oforiginal references to
the data summarized here can be found in
Polychlorinated Dibenzo-para-Dioxins and
PolychlorinatedDibenzofiurans (1). Human
exposure to TCDD or other PCDDs
because ofindustrial or accidental exposure
or the ingestion ofPCDFs in PCB-conta-
minated rice oil has been associated with
chloracne and alterations in liver enzyme
levels. Changes in the immune system
and glucose metabolism have also been
observed in adults. Infants exposed to
PCDDs and PCDFs through breast milk
exhibit alterations in thyroid hormone
levels and possible neurobehavioral and
neurologic deficits.
The extraordinary toxicity ofTCDD
and related 2,3,7,8-substituted PCDDs has
been demonstrated in manyanimal species.
The lethal dose ofTCDD, however, varies
more than 5000-fold between the guinea
pig (most sensitive) and the hamster (least
sensitive). In all mammalian species tested,
lethal doses ofTCDD result in delayed
death preceded by excessive body weight
loss (wasting). Other signs of TCDD
intoxication consistent among most species
include thymus atrophy; hypertrophy or
hyperplasia ofhepatic, gastrointestinal,
urogenital, and cutaneous epithelia; atro-
phy ofthe gonads; subcutaneous edema;
and systemic hemorrhage.
Most human studies on reproductive
effects ofPCDDs concerned paternal expo-
sure, usually long after high exposure had
occurred; these provide limited evidence of
alterations in hormone levels, sperm char-
acteristics, and immune system. In experi-
mental animals, however, TCDD is both a
developmental and reproductive toxicant.
The developing embryo/fetus appears to be
more sensitive than adult animals to the
adverse effects ofTCDD. Perturbations of
the reproductive system in adult animals
require overtly toxic doses. In contrast,
effects on the developing organism occur at
doses more than two orders ofmagnitude
lower than those that are toxic to the
mother. Sensitive targets include the devel-
oping reproductive, nervous, and immune
systems. In the case of PCDFs, observa-
tions of children born after the Yusho
(35,36) andYu-cheng (37) incidents show
signs of intrauterine growth retardation
and congenital anomalies at birth and
deficit of cognitive development up to 7
years ofage. Eight of39 children exposed
in utero died after birth. Characteristic
effects in survivors include defects in mus-
culoskeletal development and pigmenta-
tion and psychomotor delays. Several
PCDFs are teratogenic in mice, causing
cleft palate and hydronephrosis. 2,3,4,7,8-
PentaCDF leads to persistent reproductive
effects (reduced sperm count, structural
alterations ofthe female genital tract) fol-
lowing prenatal exposure. 2,3,4,7,8-
PentaCDF also promotes the growth of
surgically induced endometriosis in mice.
PCDDs cause suppression ofboth cell-
mediated and humoral immunity.
Significant reduction ofthymusweight and
suppression ofthe activity ofcytotoxic T
lymphocytes was observed in several
species. The numbers ofT helper memory
cells were decreased in mice, while in mar-
mosets dose-dependent fluctuations ofthis
cell type in peripheral blood were also
observed. Alterations of some immune
responses can be observed after exposure to
doses below 0.1 pg TCDD/kg in mice and
nonhuman primates. For example, PCDDs
have the potential to suppress resistance to
bacterial, viral, and parasitic challenges in
mice; a single dose of 10 ng TCDD/kg to
mice resulted in an increase in mortality
from influenza infection and is the lowest
dose that produces an adverse effect yet
reported for this compound (42).
In addition to these system and organ
specific effects ofTCDD, exposure of ani-
mals leads to an increase in cell prolifera-
tion, hyperplasia, and neoplasia in a
number oftissues, although it is difficult to
define a role based on effective doses for
any ofthese processes (which are normally
measured over short-term periods) in neo-
plasia. Changes in cell growth homeostasis
occur during tumor promotion and may be
related to alterations in apoptosis, growth
factor expression, and growth factor and
nuclear hormone receptor levels. It would
appear, however, that the primary effects of
TCDD and probably other PCDDs and
PCDFs are not mediated by a direct-acting
genotoxic mode ofaction.
The toxicity ofTCDD to mice geneti-
cally segregates with the high-affinity allele
for the cytosolic aryl (aromatic) hydro-
carbon receptor (AhR), and the relative
toxicities of other PCDD congeners are
associated with their ability to bind to the
receptor. The AhR binding affinities
of 2,3,7,8-TCDF and 1,2,3,7,8- and
2,3,4,7,8-pentaCDF are ofthe same order
ofmagnitude as that observed for TCDD.
PCDDs with at least three lateral chlorine
atoms bind with some affinity to the AhR.
If, as is currently believed, most if not all
effects ofTCDD arise from an initial high
affinity interaction with the AhR, then it
would appear that the biochemical and
toxicologic consequences of PCDF expo-
sure are the result of a similar mode of
action. The limited amount ofdata avail-
able on carcinogenicity for congeners other
than TCDD indicate that carcinogenic
potency is also proportional to AhR affin-
ity. Based on this evidence all PCDDs and
PCDFs are believed to act through a simi-
lar mechanism and require an initial bind-
ing to the AhR. Binding ofTCDD to the
AhR results in transcriptional activation of
a battery ofTCDD-responsive genes, but
currently no responsive gene has been
proven to have a definitive role in the
mechanism ofcarcinogenesis byTCDD.
Overall Evaluations
After considering the human and animal
cancer data together with all of the other
experimental data, overall evaluations and
classifications were made by the IARC
Working Group members. The Working
Group concluded that TCDD is carcino-
genic to humans(group 1).
In making the overall evaluation, the
Working Group considered the following
supportingevidence:
* TCDD is a multisite carcinogen in
experimental animals and has been
shown by several lines of evidence to
act through a mechanism involving
theAhR.
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* This receptor is highly conserved in an
evolutionary sense and functions the
same way in humans as in experimental
animals.
* Tissue concentrations are similar both
in heavily exposed human populations
in which an increased overall cancer risk
was observed and in rats exposed to car-
cinogenic dosage regimens in bioassays.
Other PCDDs are not classifiable as to
theircarcinogenicity to humans(group 3).
Dibenzo-p-dioxin is notclssifiable as to
itscarcinogenicity to humans(group 3).
PCDFs are not classifiable as to their
carcinogenicity to humans (group 3).
Discussion
A number of questions arise from these
Working Group evaluations, some of
which were partially addressed during the
IARC 1997 meeting (1). The following
discussion of these questions has been
made without reference to the Working
Group members.
Is it unusual to base an epidemiologic
evaluation on an aggregation ofmortality
due to all cancers combined? The usual sit-
uation is for mortality from one or a small
number ofspecific tumors to be associated
with an exposure. Although tobacco smok-
ing is causally related to deaths from tumors
in a number oforgans, statistical signifi-
cance has been repeatedly shown for the
relationship with specific individual tumor
types. Why should TCDD be treated dif-
ferently? There are at least two proffered
reasons. Few people in a small number of
populations have been exposed to high lev-
els ofTCDD; hence, ifit is a risk factor for
several tumor types, perhaps the incidence
ofaparticular tumor type may never be ele-
vated to a level ofsignificance. A parallel, if
imperfect, example is environmental
tobacco smoke (i.e., smoking-related
tumors among nonsmokers). The average
relative risk oflung cancer from passive
smoking, as estimated by meta-analysis ofa
large number ofepidemiologic studies, is
about 1.2 (43), whereas among tobacco
smokers the relative risk for lung cancer can
be 20.0 or more. The U.S. Environmental
Protection Agency has performed an infor-
mal meta-analysis ofTCDD and related
chemicals and soft-tissue sarcoma, but the
more prominent cancers deserving such
treatment must include lung cancer because
it is the one that shows overall the highest
increased risk. The other proffered reason is
that TCDD is a powerful tumor promoter
but does not initiate a carcinogenic process
itself. In a particular studied population
where TCDD is a common exposure,
segments ofthat population may have been
exposed to different initiating agents, each
with a different organ specificity. Ideally, of
course, these factors should have been taken
into account in the study analysis for possi-
ble confounders. One specific example
relevant to these evaluations is the Yusho
incident in Japan (35,36). Although the
exposure in Japan was to PCDFs, not
PCDDs, it was considered that the biologic
effects ofboth types ofchemicals are medi-
ated by the AhR; consequently, differences
in the type ofcancer outcome presumably
would be due to differences in the initiating
agent. Japan is an area ofmoderately high
prevalence of hepatitis virus and both
hepatitis B virus (HBV) and hepatitis C
virus (HCV) are already recognized liver
cancer risk factors (44). Accordingly, the
action ofPCDFs may be to promote the
emergence ofliver tumors in people carry-
ing HBV or HCV. Ifthis hypothesis is cor-
rect, a similar pattern oftumor incidence
would also be expected to emerge in
Taiwan, which is an area ofhigh HBV and
HBC prevalence (45-48).
Why was chloracne not used as an
indicator ofhigh exposure and then these
populations examined for their cancer risk?
Frequently, blood or serum concentrations
of many PCDDs and PCDFs were avail-
able and these were, understandably, con-
sidered to be more reliable measures of
internal dose. [Note, however, that chlo-
racne occurred in about 80% ofYusho
patients in Japan (35,36) and 50-75% of
Yu-cheng patients in Taiwan (37) after the
ingestion of contaminated rice oil.]
Although this is probably correct, blood
levels alone do not give any indication of
individual susceptibility. If the conse-
quences of exposure to these compounds
are dictated by interaction with the AhR
(as argued by many investigators), the
development ofchloracne in some individ-
uals and not in others may indicate suscep-
tibility differences. These differences may
also include cancer development. It is
arguable that some post-AhR events could
dispose towards chloracne in some individ-
uals, rather than the chemical-receptor
interaction itself. Such an argument does
nothing to substantiate a greater value ofa
chemical measurement over a biologic
response as an exposure indicator.
If it is indeed correct to state that all
biologic actions of these compounds are
consequences oftheir interaction with the
AhR, why were the PCDDs other than
TCDD and the PCDFs not classified as
possible human carcinogens (group 2B)
when they also interact with the AhR? The
binding constants vary over several orders
of magnitude, the constant for TCDD
being the greatest. Although a theoretical
possibility presumably exists for any of
these compounds to be carcinogenic,
receptor binding ofonly a few is envisaged
to be toxicologically significant. Such an
argument runs counter to the objective of
the IARC Monographs, which is hazard
identification, not risk assessment.
However, hazard identification always
depends on three basic factors: that an
exposure has occurred, that an investiga-
tion has been made, and that the investiga-
tion had sufficient statistical power to
detect a difference between exposed sub-
jects and referents. These principles apply
equally to epidemiology and animal experi-
ments, are inescapable and, in experimental
situations, the last factor contributes to the
increased proportion of tested chemicals
that has been identified as carcinogens
during the last quarter century (49).
The mechanistic support for TCDD
being a human carcinogen appears limited
to its interaction with the AhR and
depends on the presumed involvement of
this receptor in most, ifnot all, toxicologic
consequences ofexposure and the presence
ofthis receptor with similar titrations in all
ofthe animal species tested. However, no
specific subsequent steps were proposed to
lead to the development of cancers.
Instead, it was considered by the Working
Group that the plethora of events that
could result fromAhR interaction-in par-
ticular the transcriptional activation of a
number of genes included currently
unidentified steps in a carcinogenic path-
way. The Working Group decided that it
was more appropriate to apply mechanistic
arguments to the evaluation ofcarcinogenic
hazards presented by agents for which sub-
stantial bioassay or epidemiologic data
were available. In effect, mechanistic con-
siderations were viewed as supportive only
in the case ofTCDD, for which ample
bioassay data and considerable epidemio-
logic data (which, by themselves, provide
limited evidence of carcinogenicity to
humans) were available.
Is TCDD a highly potent carcinogen?
The dose levels required to produce signifi-
cant increases in tumor incidence in
rodents are very low. As a standardized
measure ofpotency, Gold et al. (50) calcu-
lated that the median toxic dose for
TCDD-induced hepatocellular carcinomas
in female rats in the Kociba et al.
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(29) experiment was 0.065 ligIkg body
weight/day normalized to a lifespan of
2 years. This is the lowest value of any
studied compound. However, the doses
required for a carcinogenic effect are also
very close to those doses in the same
species that produce toxicity in a much
shorter time; hence, the demonstrable
carcinogenic dose window is narrow.
Furthermore, in contrast to certain other
carcinogens, the increased proportion of
tumor-bearing animals is not great. It is
dear from studies ofother agents that car-
cinogenic potency may vary greatly
between species (e.g., aflatoxin B1 in rats
and mice) and attempts to extrapolate
potency data from rodents to man must be
viewed with caution.
With respect to PCDF/PCB contami-
nation ofrice oil, has there been adequate
explanation of the differences in cancer
incidence and mortality between Japan
(where liver cancer mortality is currently
3-fold higher in the affected population)
and Taiwan (where there is no increase in
liver tumors)? The available time for cancer
development in Japan is 22 years, com-
pared with only 12 years in Taiwan. Thus,
the current epidemiologic evidence is
judged to be inadequate but in a few more
years this situation may change as the fol-
low-up period for Taiwan gets doser to the
current Japanese follow-up. However, two
features ofthe Japanese data suggest that
this prediction is not inevitable. Differences
in cancer mortality between the Japanese
exposed and referent populations are not
monotonically increasing with time. One
example is mentioned in Polychlorinated
Dibenzo-para-Dioxins andPolychlorinated
Dibenzofurans (1): the relative risk for liver
cancer mortality in men at 15 years was 5.6
(p<0.01), whereas it was 3.4 (p<0.01) at
22 years. Another example is the relative
risk for mortality from cancer ofthe lung,
trachea, and bronchus, which at 15 years
was 3.3 (p<0.01) but was 1.8 at 22 years
(no longer significant) (35,36). However,
these changes remain consistent with
PCDF exposure being a risk factor. If, as is
proposed, the principal action of these
compounds is tumor promotion, the total
cancer burden may not have changed but
the emergence ofcertain cancers may have
been accelerated. If this argument is to
stand, similar evidence ofearly emergence
ofspecific cancers, followed by the slower
increase of these same cancers in referent
populations, should be evident. We are not
aware that this has occurred.
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